EQRx is a Cambridge-based company that aims to disrupt the traditional innovation and pricing model of biopharma by developing and commercializing less expensive, branded medications that are equally good or better than the market leader(s). EQRx intends to achieve innovator-type operating margins at a radically lower price point. EQRx believes it can deliver on this vision by developing deep partnerships with US and ex-US payers who are highly incentivized by price to shift market share to EQRx, thus substantially reducing the need for sales and marketing infrastructure, and meaningfully streamlining R&D costs. EQRx is a purpose-built disruptor at scale, remaking medicine to bend the cost curve in drug pricing.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.